QLF32101 / Qilu Pharma - LARVOL DELTA

A PHASE 1, DOSE-ESCALATION STUDY OF QLF32101, A CLL1/CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) (EHA 2024) - P1 | "Preliminary data of QLF32101 dosed up to 18 µg provide early evidences of acceptable safety profile, drugtolerability, and anti-leukemic activity. Dose escalation is ongoing and updated data will be presented."

Clinical • P1 data • Acute Myelogenous Leukemia • Dyslipidemia • Endocrine Disorders • Hypertriglyceridemia • Infectious Disease • Leukopenia • Neutropenia • Pneumonia • Respiratory Diseases • Thrombocytopenia

A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - P1 | N=122 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd. | N=62 ➔ 122

Enrollment change • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - P1 | N=62 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology